MS treatment: What is Plan B?
December 5, 2013…similar efficacy with respect to the proportion of patients who are relapse-free and/or progression-free (Braune et al. J Neurol 2013; epublished September 6, 2013). A number of open-label studies have indicated that there are clinical benefits when patients are switched from an injectable to fingolimod. In the TRANSFORMS extension, there were significant improvements in the annualized relapse rate (ARR) and MRI lesion number in the 12 months afte…